Plasma microRNA Signature as Predictive Marker of Clinical Response to Therapy During Multiple Sclerosis.

ABSTRACT:

Objective

Despite the availability of effective therapies for Multiple Sclerosis (MS), the unpredictable nature of disease progression and the variability in individual treatment outcomes call for reliable biomarkers. This pilot study aims to investigate the potential of plasma circulating microRNAs (miRNAs) as predictive biomarkers for clinical responses to dimethyl fumarate (DMF), a widely used oral treatment for MS.

Methods

Peripheral blood samples were collected from nineteen treatment-naïve people with relapsing-remitting MS (pwRRMS) before and after 3, 6, 12, and 24 months of DMF administration, as well as from nineteen healthy individuals. MiRNAs were quantified by RT-qPCR after plasma RNA extraction, and peripheral blood immune cells were analyzed by flow cytometry.

SUBMITTER: Carbone F 

PROVIDER: S-EPMC12343307 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature